FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

Merck Keytruda sBLA for Endometrial Cancer

[ Price : $8.95]

FDA accepte for priority review a Merck supplemental BLA for Keytruda in combination with standard-of-care chemotherapy for treati...

ARS Pharma Responding to Complete Response

[ Price : $8.95]

ARS Pharmaceuticals says new study data will be submitted in the second quarter as part of a response to a 9/2023 FDA complete res...

API Manufacturing Deviations at Sichuan Deebio

[ Price : $8.95]

FDA warns Chinas Sichuan Deebio Pharmaceutical Co. about significant deviations in manufacturing active pharmaceutical ingredients...

Clinical Hold on RAPT Zelnecirnon Studies

[ Price : $8.95]

A report of a patients liver failure leads to an FDA clinical hold against two RAPT Therapeutics Phase 2 trials involving zelnecir...

Why Industry Resists FDA Quality Management Efforts

[ Price : $8.95]

PDC Pharma Strategy CEO Penelope Przekop says there are several reasons why the drug industry is not rapidly moving toward quality...

Comments Extended on Master Protocols Guide

[ Price : $8.95]

Federal Register notice: FDA extends the comment period on a 12/22 notice for its Master Protocols for Drug and Biological Product...

Iovance Melanoma Cell Therapy Approved

[ Price : $8.95]

FDA grants accelerated approval to Iovance Biotherapeutics for Amtagvi, a cellular therapy indicated for treating certain adult pa...

sBLA for Elevidys Conversion to Traditional Approval

[ Price : $8.95]

FDA accepts for priority review a Sarepta Therapeutics supplemental BLA for Elevidys (delandistrogene moxeparvovec-rokl) to conver...

Xolair Approved for Reducing Allergic Reactions

[ Price : $8.95]

FDA approves a Novartis supplemental BLA for Xolair (omalizumab) for reducing allergic reactions related to accidental exposure to...

Metabolic Disease Panel Notice Amended

[ Price : $8.95]

Federal Register notice: FDA amends a 12/12/2023 notice requesting nominations for voting members to serve on CDERs Genetic Metabo...